Nothing said here yet.
to join the conversation.
| Rider Michael JGlobal General Counsel | Sell | 400 | $102.0K | Fri, Oct 23 |
| Farrell Michael J.Chairman and CEO | Sell | 4,991 | $1.1M | Wed, Oct 7 |
| Farrell Michael J.Chairman and CEO | Sell | 4,991 | $1.1M | Tue, Sep 8 |
| FARRELL PETER CDirector | Sell | 970 | $227.7K | Wed, Sep 2 |
| Thomas H Tuberville | Sell | $8.0K | Fri, May 3 | Wed, Aug 5 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in calendar Q3 2026 (fiscal Q1 2027), with sales up 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.
ResMed (RMD) just posted quarterly results that topped analyst expectations on both earnings and revenue, while reaffirming its full year outlook and highlighting firm demand for sleep devices, masks, and digital health tools.
Moby summary of ResMed Inc.'s Q1 2027 earnings call
ResMed's first-quarter fiscal 2027 earnings and revenues top estimates as sustained sleep device demand, productivity gains and gross margin expansion drive growth.
Medical device company ResMed (NYSE:RMD) announced better-than-expected revenue in calendar Q3 2026 (fiscal Q1 2027), with revenue rising 5.9% year on year to $1.41 billion. Its non-GAAP profit of $2.91 per share was 8.9% above analysts’ consensus estimates.
ResMed (NYSE:RMD) reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% from a year earlier on a reported basis and 7% on a core constant-currency basis, as growth in sleep devices, masks and residential care software offset declines in…
SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $418.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.